BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Treprostinil (Tyvaso) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Treprostinil (Tyvaso)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06969573-520@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Treprostinil (Tyvaso): Phase 2 readout est. (NCT06969573)
DESCRIPTION:Treprostinil (Tyvaso)\, phase 2.\nStudy: Inhaled Treprostinil f
 or Dyspnea and Exercise Intolerance in Mild COPD\nEstimated primary comple
 tion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/treprostinil-tyvaso#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06969573
URL:https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07116681-520@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Treprostinil (Tyvaso): Phase 1 readout est. (NCT07116681)
DESCRIPTION:Treprostinil (Tyvaso)\, phase 1.\nStudy: Effects of Inhaled Tre
 prostinil on Exercise Performance in Exercise Induced Pulmonary Hypertensi
 on\nEstimated primary completion: 1 July 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07116681
URL:https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07037836-520@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Treprostinil (Tyvaso): Phase 2 readout est. (NCT07037836)
DESCRIPTION:Treprostinil (Tyvaso)\, phase 2.\nStudy: Inhaled Treprostinil (
 Tyvaso Nebulizer) For COPD Patients With Hypoxemia\nEstimated primary comp
 letion: 1 July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 treprostinil-tyvaso#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07037836
URL:https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05943535-520@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Treprostinil (Tyvaso): Phase 3 readout est. (NCT05943535)
DESCRIPTION:Treprostinil (Tyvaso)\, phase 3.\nStudy: Study of the Efficacy 
 and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary 
 Fibrosis (TETON-PPF)\nEstimated primary completion: November 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05943535
URL:https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07837830-520@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Treprostinil (Tyvaso): Phase 1 readout est. (NCT07837830)
DESCRIPTION:Treprostinil (Tyvaso)\, phase 1.\nStudy: Early Intervention Wit
 h Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hype
 rtension (EPIH)\nEstimated primary completion: December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07837830
URL:https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07177703-520@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Treprostinil (Tyvaso): Phase 2 readout est. (NCT07177703)
DESCRIPTION:Treprostinil (Tyvaso)\, phase 2\, Pulmonary Arterial Hypertensi
 on.\nStudy: Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmo
 nary Arterial Hypertension\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/treprostinil-tyvaso
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071
 77703
URL:https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923591-520@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Treprostinil (Tyvaso): Phase 2 readout est. (NCT07923591)
DESCRIPTION:Treprostinil (Tyvaso)\, phase 2.\nStudy: Study of Treprostinil 
 Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hy
 pertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
 \nEstimated primary completion: May 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07923591
URL:https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04905693-520@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Treprostinil (Tyvaso): Phase 3 readout est. (NCT04905693)
DESCRIPTION:Treprostinil (Tyvaso)\, phase 3\, Idiopathic Pulmonary Fibrosis
 .\nStudy: Extension Study of Inhaled Treprostinil in Subjects With Fibroti
 c Lung Disease\nEstimated primary completion: December 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT04905693
URL:https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923526-520@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20340930
DTEND;VALUE=DATE:20341001
SUMMARY:Treprostinil (Tyvaso): Phase 2/3 readout est. (NCT07923526)
DESCRIPTION:Treprostinil (Tyvaso)\, phase 2/3.\nStudy: An Open-Label Extens
 ion Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmon
 ary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH
 -COPD)\nEstimated primary completion: September 2034. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07923526
URL:https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
